{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T05:19:35Z","timestamp":1790399975397,"version":"4.1.0"},"reference-count":89,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jfma.2025.06.033","type":"journal-article","created":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T15:22:52Z","timestamp":1750432972000},"page":"895-901","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Four decades of the RET gene: From discovery to tumor-agnostic therapy"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2803-2683","authenticated-orcid":false,"given":"Masahide","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib1","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0092-8674(85)90115-1","article-title":"Activation of a novel human transforming gene, ret, by DNA rearrangement","volume":"42","author":"Takahashi","year":"1985","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib2","first-page":"1378","article-title":"ret transforming gene encodes a fusion protein homologous to tyrosine kinases","volume":"7","author":"Takahashi","year":"1987","journal-title":"Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib3","first-page":"1853","article-title":"Developmentally regulated expression of a human \u201cfinger\u201d-containing gene encoded by the 5\u2032 half of the ret transforming gene","volume":"8","author":"Takahashi","year":"1988","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib4","first-page":"571","article-title":"Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains","volume":"3","author":"Takahashi","year":"1988","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jfma.2025.06.033_bib5","first-page":"805","article-title":"Isolation of ret proto-oncogene cDNA with an amino-terminal signal sequence","volume":"4","author":"Takahashi","year":"1989","journal-title":"Oncogene"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib6","first-page":"1087","article-title":"cDNA cloning of mouse ret proto-oncogene and its sequence similarity to the cadherin superfamily","volume":"8","author":"Iwamoto","year":"1993","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib7","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a009134","article-title":"Structure and physiology of the RET receptor tyrosine kinase","volume":"5","author":"Ib\u00e1\u00f1ez","year":"2013","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib8","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1359-6101(01)00012-0","article-title":"The GDNF\/RET signaling pathway and human diseases","volume":"12","author":"Takahashi","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4\u20135","key":"10.1016\/j.jfma.2025.06.033_bib9","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.cytogfr.2005.05.010","article-title":"RET tyrosine kinase signaling in development and cancer","volume":"16","author":"Arighi","year":"2005","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5111","key":"10.1016\/j.jfma.2025.06.033_bib10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1126\/science.8493557","article-title":"GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons","volume":"260","author":"Lin","year":"1993","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib11","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/nrn812","article-title":"The GDNF family: signalling, biological functions and therapeutic value","volume":"3","author":"Airaksinen","year":"2002","journal-title":"Nat Rev Neurosci"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib12","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s00441-020-03262-1","article-title":"Intracellular RET signaling pathways activated by GDNF","volume":"382","author":"Kawai","year":"2020","journal-title":"Cell Tissue Res"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib13","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2183\/pjab.98.008","article-title":"RET receptor signaling: function in development, metabolic disease, and cancer","volume":"98","author":"Takahashi","year":"2022","journal-title":"Proc Jpn Acad Ser B Phys Biol Sci"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib14","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/S0092-8674(00)81311-2","article-title":"GDNF-induced activation of the Ret protein tyrosine kinase is mediated by GDNFR-\u03b1, a novel receptor for GDNF","volume":"85","author":"Jing","year":"1996","journal-title":"Cell"},{"issue":"6586","key":"10.1016\/j.jfma.2025.06.033_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/382080a0","article-title":"Characterization of a multicomponent receptor for GDNF","volume":"382","author":"Treanor","year":"1996","journal-title":"Nature"},{"issue":"6634","key":"10.1016\/j.jfma.2025.06.033_bib16","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/42722","article-title":"A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor","volume":"387","author":"Klein","year":"1997","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib17","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aau4202","article-title":"Cryo-EM structure of the activated RET signaling complex reveals the importance of its cysteine-rich domain","volume":"5","author":"Bigalke","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.jfma.2025.06.033_bib18","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.47650","article-title":"Cryo-EM analyses reveal the common mechanism and diversification in the activation of RET by different ligands","volume":"8","author":"Li","year":"2019","journal-title":"eLife"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib19","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.str.2020.12.012","article-title":"A two-site flexible clamp mechanism for RET-GDNF-GFR\u03b11 assembly reveals both conformational adaptation and strict geometric spacing","volume":"29","author":"Adams","year":"2021","journal-title":"Structure"},{"issue":"6461","key":"10.1016\/j.jfma.2025.06.033_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/367380a0","article-title":"Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret","volume":"367","author":"Schuchardt","year":"1994","journal-title":"Nature"},{"issue":"6586","key":"10.1016\/j.jfma.2025.06.033_bib21","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/382070a0","article-title":"Renal agenesis and the absence of enteric neurons in mice lacking GDNF","volume":"382","author":"S\u00e1nchez","year":"1996","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib22","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0896-6273(00)80514-0","article-title":"GFR\u03b11 is an essential receptor component for GDNF in the developing nervous system and kidney","volume":"21","author":"Cacalano","year":"1998","journal-title":"Neuron"},{"issue":"18","key":"10.1016\/j.jfma.2025.06.033_bib23","doi-asserted-by":"crossref","first-page":"8026","DOI":"10.1128\/MCB.24.18.8026-8036.2004","article-title":"A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia","volume":"24","author":"Jijiwa","year":"2004","journal-title":"Mol Cell Biol"},{"issue":"5457","key":"10.1016\/j.jfma.2025.06.033_bib24","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1126\/science.287.5457.1489","article-title":"Regulation of cell fate decision of undifferentiated spermatogonia by GDNF","volume":"287","author":"Meng","year":"2000","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib25","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2443.2008.01171.x","article-title":"GDNF-mediated signaling via RET tyrosine 1062 is essential for maintenance of spermatogonial stem cells","volume":"13","author":"Jijiwa","year":"2008","journal-title":"Genes Cells"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib26","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0896-6273(00)81087-9","article-title":"Gene targeting reveals a critical role for neurturin in the development and maintenance of enteric, sensory, and parasympathetic neurons","volume":"22","author":"Heuckeroth","year":"1999","journal-title":"Neuron"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(00)81086-7","article-title":"Retarded growth and deficits in the enteric and parasympathetic nervous system in mice lacking GFR\u03b12, a functional neurturin receptor","volume":"22","author":"Rossi","year":"1999","journal-title":"Neuron"},{"issue":"7675","key":"10.1016\/j.jfma.2025.06.033_bib28","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nature24042","article-title":"Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15","volume":"550","author":"Hsu","year":"2017","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.jfma.2025.06.033_bib29","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/nm.4392","article-title":"GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates","volume":"23","author":"Mullican","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jfma.2025.06.033_bib30","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/nm.4394","article-title":"GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand","volume":"23","author":"Yang","year":"2017","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.jfma.2025.06.033_bib31","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/nm.4393","article-title":"The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL","volume":"23","author":"Emmerson","year":"2017","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib32","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.7150\/jca.50376","article-title":"GDF15\/GFRAL pathway as a metabolic signature for cachexia in patients with cancer","volume":"12","author":"Ahmed","year":"2021","journal-title":"J Cancer"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib33","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/0092-8674(90)90659-3","article-title":"PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas","volume":"60","author":"Grieco","year":"1990","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib34","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1172\/JCI115743","article-title":"Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype","volume":"89","author":"Santoro","year":"1992","journal-title":"J Clin Investig"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib35","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","year":"2014","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib36","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41698-023-00347-2","article-title":"Genomic landscape of 891 RET fusions detected across diverse solid tumor types","volume":"7","author":"Parimi","year":"2023","journal-title":"npj Precis Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1385\/EP:13:1:03","article-title":"RET\/PTC rearrangement in thyroid tumors","volume":"13","author":"Nikiforov","year":"2002","journal-title":"Endocr Pathol"},{"issue":"17","key":"10.1016\/j.jfma.2025.06.033_bib38","doi-asserted-by":"crossref","first-page":"7176","DOI":"10.1158\/0008-5472.CAN-08-0293","article-title":"RET\/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose","volume":"68","author":"Hamatani","year":"2008","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib39","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/nm.2644","article-title":"KIF5B-RET fusions in lung adenocarcinoma","volume":"18","author":"Kohno","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib40","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nm.2658","article-title":"RET, ROS1 and ALK fusions in lung cancer","volume":"18","author":"Takeuchi","year":"2012","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib41","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/nm.2673","article-title":"Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies","volume":"18","author":"Lipson","year":"2012","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib42","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/cr.2012.27","article-title":"Identification of RET gene fusion by exon array analyses in \u201cpan-negative\u201d lung cancer from never smokers","volume":"22","author":"Li","year":"2012","journal-title":"Cell Res"},{"issue":"11","key":"10.1016\/j.jfma.2025.06.033_bib43","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib44","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1073\/pnas.89.5.1616","article-title":"Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET\/PTC","volume":"89","author":"Pierotti","year":"1992","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib45","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The importance of the RET gene in thyroid cancer and therapeutic implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib46","article-title":"Catalog of 5\u2032 fusion partners in RET+ NSCLC circa 2020 JTO clin","volume":"1","author":"Ou","year":"2020","journal-title":"Res Rep"},{"issue":"30","key":"10.1016\/j.jfma.2025.06.033_bib47","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.18632\/oncotarget.4325","article-title":"Identification of characterization of RET fusion in advanced colorectal cancer","volume":"6","author":"Le Rolle","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib48","doi-asserted-by":"crossref","first-page":"4821","DOI":"10.1038\/s41467-018-07341-4","article-title":"RET rearrangements are actionable alterations in breast cancer","volume":"9","author":"Paratala","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.033_bib49","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jfma.2025.06.033_bib50","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1038\/ncomms4116","article-title":"Kinase fusions are frequent in Spitz tumours and spitzoid melanomas","volume":"5","author":"Wiesner","year":"2014","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.jfma.2025.06.033_bib51","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1097\/PAS.0000000000001133","article-title":"Molecular profiling of salivary gland intraductal carcinoma revealed a subset of tumors harboring NCOA4-RET and novel TRIM27-RET fusions: a report of 17 cases","volume":"42","author":"Sk\u00e1lov\u00e1","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"10","key":"10.1016\/j.jfma.2025.06.033_bib52","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0000000000001535","article-title":"Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion","volume":"44","author":"Sk\u00e1lov\u00e1","year":"2020","journal-title":"Am J Surg Pathol"},{"issue":"6428","key":"10.1016\/j.jfma.2025.06.033_bib53","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/363458a0","article-title":"Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A","volume":"363","author":"Mulligan","year":"1993","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib54","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1093\/hmg\/2.7.851","article-title":"Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC","volume":"2","author":"Donis-Keller","year":"1993","journal-title":"Hum Mol Genet"},{"issue":"6461","key":"10.1016\/j.jfma.2025.06.033_bib55","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/367375a0","article-title":"A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma","volume":"367","author":"Hofstra","year":"1994","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib56","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1073\/pnas.91.4.1579","article-title":"Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B","volume":"91","author":"Carlson","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib57","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/nrendo.2016.11","article-title":"A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma","volume":"12","author":"Romei","year":"2016","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib58","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1128\/MCB.15.3.1613","article-title":"Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations","volume":"15","author":"Asai","year":"1995","journal-title":"Mol Cell Biol"},{"issue":"5196","key":"10.1016\/j.jfma.2025.06.033_bib59","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1126\/science.7824936","article-title":"Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B","volume":"267","author":"Santoro","year":"1995","journal-title":"Science"},{"issue":"14","key":"10.1016\/j.jfma.2025.06.033_bib60","first-page":"2870","article-title":"Biological properties of Ret with cysteine mutations correlate with multiple endocrine neoplasia type 2A, familial medullary thyroid carcinoma, and Hirschsprung's disease phenotype","volume":"57","author":"Ito","year":"1997","journal-title":"Cancer Res"},{"issue":"19","key":"10.1016\/j.jfma.2025.06.033_bib61","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1001\/jama.1996.03540190047028","article-title":"The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis","volume":"276","author":"Eng","year":"1996","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.31662\/jmaj.2020-0021","article-title":"Roles of the RET proto-oncogene in cancer and development journal","volume":"3","author":"Takahashi","year":"2020","journal-title":"JMA J"},{"issue":"5","key":"10.1016\/j.jfma.2025.06.033_bib63","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET kinase domain mutations perturb the autophosphorylation trajectory by enhancing substrate presentation in trans","volume":"53","author":"Plaza-Menacho","year":"2014","journal-title":"Mol Cell"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib64","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1006\/bbrc.2000.2227","article-title":"A two-hit model for development of multiple endocrine neoplasia type 2B by RET mutations","volume":"268","author":"Iwashita","year":"2000","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib65","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2025.06.033_bib66","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.trecan.2021.07.003","article-title":"Precision therapy for RET-altered cancers with RET inhibitors","volume":"7","author":"Thein","year":"2021","journal-title":"Trends Cancer"},{"issue":"3","key":"10.1016\/j.jfma.2025.06.033_bib67","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1158\/2159-8290.CD-18-0839","article-title":"A phase I\/Ib trial of the VEGFR-sparing multikinase RET inhibitor RXDX-105","volume":"9","author":"Drilon","year":"2019","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.033_bib68","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1093\/annonc\/mdy137","article-title":"Selective RET kinase inhibition for patients with RET-altered cancers","volume":"29","author":"Subbiah","year":"2018","journal-title":"Ann Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib69","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1158\/2159-8290.CD-18-0338","article-title":"Precision targeted therapy with BLU-667 for RET-driven cancers","volume":"8","author":"Subbiah","year":"2018","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.jfma.2025.06.033_bib70","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1056\/NEJMoa2005653","article-title":"Efficacy of Selpercatinib in RET fusion-positive non-small-cell lung cancer","volume":"383","author":"Drilon","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jfma.2025.06.033_bib71","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJMoa2005651","article-title":"Efficacy of Selpercatinib in RET-altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jfma.2025.06.033_bib72","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1200\/JCO-24-02076","article-title":"Selpercatinib in RET fusion-positive non-small cell lung cancer: final safety and efficacy, including overall survival, from the LIBRETTO-001 phase I\/II trial","volume":"43","author":"Gautschi","year":"2025","journal-title":"J Clin Oncol"},{"issue":"27","key":"10.1016\/j.jfma.2025.06.033_bib73","doi-asserted-by":"crossref","first-page":"3187","DOI":"10.1200\/JCO.23.02503","article-title":"Durability of response with selpercatinib in patients with RET-activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.jfma.2025.06.033_bib74","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.033_bib75","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"10.1016\/j.jfma.2025.06.033_bib76","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.annonc.2022.08.002","article-title":"Safety and efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial","volume":"33","author":"Griesinger","year":"2022","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1089\/thy.2023.0363","article-title":"Pralsetinib in patients with advanced\/metastatic rearranged during transfection (RET)-altered thyroid cancer: updated efficacy and safety data from the ARROW study","volume":"34","author":"Subbiah","year":"2024","journal-title":"Thyroid"},{"issue":"15","key":"10.1016\/j.jfma.2025.06.033_bib78","doi-asserted-by":"crossref","first-page":"4160","DOI":"10.1158\/1078-0432.CCR-21-0800","article-title":"Intracranial efficacy of selpercatinib in RET fusion-positive non-small cell lung cancers on the LIBRETTO-001 trial","volume":"27","author":"Subbiah","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"20","key":"10.1016\/j.jfma.2025.06.033_bib79","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1056\/NEJMoa2309719","article-title":"Phase 3 Trial of selpercatinib in advanced RET-mutant medullary thyroid cancer","volume":"389","author":"Hadoux","year":"2023","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.jfma.2025.06.033_bib80","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.jfma.2025.06.033_bib81","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/s41591-022-01931-y","article-title":"Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1\/2 ARROW trial","volume":"28","author":"Subbiah","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib82","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41467-018-02994-7","article-title":"A secondary RET mutation in the activation loop conferring resistance to vandetanib","volume":"9","author":"Nakaoku","year":"2018","journal-title":"Nat Commun"},{"issue":"4","key":"10.1016\/j.jfma.2025.06.033_bib83","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"RET solvent front mutations mediate acquired resistance to selective RET inhibition in RET-driven malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib84","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jfma.2025.06.033_bib85","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41698-021-00188-x","article-title":"The L730V\/I RET roof mutations display different activities toward pralsetinib and selpercatinib","volume":"5","author":"Shen","year":"2021","journal-title":"npj Precis Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2025.06.033_bib86","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jfma.2025.06.033_bib87","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0224","article-title":"Mechanisms of resistance to RET-directed therapies","volume":"32","author":"Clifton-Bligh","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"24","key":"10.1016\/j.jfma.2025.06.033_bib88","doi-asserted-by":"crossref","first-page":"8839","DOI":"10.3390\/molecules27248839","article-title":"Precious gene: the application of RET-altered inhibitors","volume":"27","author":"Gou","year":"2022","journal-title":"Molecules"},{"issue":"9","key":"10.1016\/j.jfma.2025.06.033_bib89","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625003249?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625003249?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T04:33:29Z","timestamp":1758947609000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625003249"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":89,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0929664625003249"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.033","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Four decades of the RET gene: From discovery to tumor-agnostic therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.06.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}